Reprogrammed CD8⁺ T-Lymphocytes Isolated from Bone Marrow Have Anticancer Potential in Lung Cancer

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• CD8+ T-lymphocytes are crucial for antitumor immunity but often dysfunctional in lung cancer patients.
• T-lymphocyte exhaustion limits the efficacy of current cancer therapies.
• Lung cancer is associated with impaired T-cell function and reduced T-cell counts.

Purpose of the Study:

• To investigate the potential of reprogrammed T-lymphocytes using MEK inhibitors and PD-1 blockers to enhance antitumor activity.
• To evaluate the efficacy of these reprogrammed T-lymphocytes in vitro and in vivo models of lung cancer.

Main Methods:

• T-lymphocytes were reprogrammed using MEK inhibitors and PD-1 blockers.
• In vitro cytotoxicity assays against Lewis lung carcinoma (LLC) cells were performed.
• In vivo studies utilized the LLC model in C57BL/6 mice to assess antitumor effects and metastasis reduction.

Main Results:

• Reprogrammed T-lymphocytes exhibited persistent CCR7 expression, apoptosis resistance, and high cytotoxicity against LLC cells.
• Administration of reprogrammed T-lymphocytes significantly reduced lung metastases in mice with LLC.
• The antitumor effect was attributed to the elimination of tumor cells, cancer stem cells, and increased cytotoxic T-lymphocyte counts.

Conclusions:

• Reprogramming T-lymphocytes with MEK inhibitors is a promising strategy to overcome T-cell exhaustion in lung cancer.
• This approach demonstrates significant antitumor effects and warrants further investigation for targeted lung cancer therapy.